Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus NEBUPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus NEBUPENT.
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE vs NEBUPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a mitochondrial electron transport inhibitor that selectively targets the cytochrome bc1 complex, disrupting pyrimidine synthesis in Plasmodium. Proguanil hydrochloride is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. The combination synergistically inhibits plasmodial replication.
Nebupent (pentamidine isethionate) is an antimicrobial agent that inhibits the synthesis of DNA, RNA, phospholipids, and proteins in protozoa. Its mechanism may involve interference with polyamine synthesis and inhibition of dihydrofolate reductase.
250 mg atovaquone/100 mg proguanil hydrochloride (1 tablet) orally once daily for prophylaxis; 4 tablets (1000 mg/400 mg) orally once daily for 3 consecutive days for treatment.
300 mg via inhalation once every 4 weeks for prophylaxis of Pneumocystis jirovecii pneumonia.
None Documented
None Documented
Atovaquone: terminal half-life 2-3 days (67-83 hours); prolonged to 4-5 days in malaria due to drug accumulation. Proguanil: terminal half-life 12-21 hours; cycloguanil 14-21 hours.
Terminal elimination half-life: 6-9 hours (prolonged in renal impairment; clinical context: supports once-daily dosing for treatment, but prophylaxis may require reduced frequency in renal dysfunction)
Atovaquone: >94% excreted unchanged in feces via biliary elimination; renal excretion minimal (<1%). Proguanil: ~40-60% excreted renally as unchanged drug and metabolites (primarily cycloguanil and 4-chlorophenylbiguanide).
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<5%)
Category A/B
Category C
Antiprotozoal
Antiprotozoal, Inhaled